According to the researchers of this study, since statins are widely used among older adults and expected to increase in use, determining the effects of statin therapy on cognition in older individuals is vital to help clinicians weigh their benefits against associated risks.“With statins being increasingly prescribed to older adults, their potential long-term effects on cognitive decline and dementia risk have attracted growing interest,” said Zhen Zhou, PhD, Menzies Institute for Medical Research at the University of Tasmania in Australia and lead author of the study.
“The present study adds to previous research by suggesting that statin use at baseline was not associated with subsequent dementia incidence and long-term cognitive decline in older adults.”.
ASPREE was a large prospective, randomized placebo-controlled trial of daily low-dose aspirin, which included 19,114 participants 65 years old or older with no prior CVD event, dementia or major physical disability, between 2010 and 2014 from Australia and the U.S.After a median of 4.7 years of follow-up, researchers found 566 incident cases of dementia (including probable AD and mixed presentations).
Compared with no statin use, statin use was not associated with risk of all-cause dementia, probable AD, or mixed presentations of dementia.
However, researchers did find interaction effects between baseline cognitive ability and statin therapy for all dementia outcomes.According to the researchers, this study has several limitations, including observational study bias, lack of data on the length of prior use of statins, and the dose of statins was not recorded in the ASPREE trial, so their effects could not be fully explored.
Researchers conclude the study must be interpreted with caution and will require confirmation by randomized clinical trials designed to explore the neurocognitive effects of statins in older populations.
Ballantyne, MD, professor at Baylor College of Medicine in Houston, said the study does have limitations that the authors address, but agreed the findings suggest statins do not contribute to cognitive decline.
“Lingering questions such as the one raised by this analysis regarding potential adverse effects of statins in individuals with mildly impaired cognition can only be answered in randomized controlled trials in the appropriate age group and population and with appropriate testing and adequate follow-up.
In the meantime, practicing clinicians can have confidence and share with their patients that short-term lipid lowering therapy in older individuals, including with statins, is unlikely to have a major impact on cognition.”.
But they do use a lead-in period in which people who have side effects drop out, so that the study is skewed from the beginning.
About 80% of my normal… It took about 3 years to get back to feeling like a human being again and I will never take Statins again.“Observational study adds to growing evidence that statin therapy is not associated with cognitive decline and dementia in older adults.” I call BALONEY on this.
I took statins TWENTY YEARS AGO – – when I was in my mid-to-late FORTIES
6 hours ago
8 hours ago
9 hours ago
9 hours ago
Get monthly updates and free resources.
CONNECT WITH US